ALS

Radicava treatment for at least one year reduces the risk of death in people with amyotrophic lateral sclerosis, U.S. real-life data show.

As of March 31, 2021, a lower proportion of patients on Radicava than controls had died from all causes (48.7% vs. 61.6%). This translated into a 27% lower risk of death, with patients on Radicava living a median of six months longer than those not treated with Radicava (median survival of 29.5 months vs. Tracheostomy is a surgical procedure that creates an opening in the windpipe for mechanical ventilation. In both groups, 208 patients (65.4%) had a history of riluzole prescription. The decisions were based on findings from the Phase 3 Study 19 clinical trial (NCT01492686), which evaluated Radicava’s safety and effectiveness in 137 adults with ALS in Japan. The poster was titled “Continued Intravenous Edaravone Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS) Increases Overall Survival Compared With No Intravenous Edaravone Treatment: Results from a US Administrative Claims Database.”